BackEnlivex Therapeutics Overview

Enlivex Therapeutics Selling, General & Admin

Selling, General & Admin expenses for ENLV.

Quarterly SG&A Expenses

$2.76M
↑ 40.83% YoY

As of Dec 31, 2025

Annual SG&A Expenses (TTM)

$5.64M
↑ 26.43% YoY

Trailing 12 months ending Dec 31, 2025

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin